Hyperglycaemia and cardiovascular disease
Hyperglycaemia and cardiovascular disease
复制标题
DOI：
10.1111/j.1365-2796.2007.01831.x
复制
发表时间：
2007-08-01
影响因子：
11.1
通讯作者：
Ryden, L.
中科院分区：
文献类型：
--
作者：
Bartnik, M.;Norhammar, A.;Ryden, L.
Bartnik M，Norhammar A，Ryden L（Karnsjukhuset Skovde; and Karolinska Institutet;斯德哥尔摩，瑞典）.高脂血症与心血管疾病（综述）。J Intern Med 2007; 262：145- 156.冠状动脉疾病和2型糖尿病是慢性疾病，其患病率显著增加。它们的巧合是常见的，显著增加死亡率和发病率。心血管疾病的风险沿着血糖浓度谱增加，该血糖浓度谱在被认为是正常的水平时已经明显。因此，需要早期检测糖代谢紊乱的策略，以找到预防心血管并发症发生或在早期阶段治疗心血管并发症的方法。更具体地说，异常葡萄糖耐量在心肌梗死患者中几乎是基于人群的对照中的两倍，并且正常葡萄糖调节确实也比在稳定性冠状动脉疾病患者中的异常葡萄糖代谢更不常见。葡萄糖耐量异常已经是急性心肌梗死后未来心血管事件的一个强有力的危险因素。因此，口服葡萄糖耐量试验应该成为所有冠状动脉疾病患者总风险评估的一部分。由于葡萄糖紊乱是常见的，易于检测，他们可能是新的二级预防工作的合适目标。
Bartnik M, Norhammar A, Ryden L (Karnsjukhuset Skovde; and Karolinska Institutet; Stockholm, Sweden). Hyperglycaemia and cardiovascular disease (Review). J Intern Med 2007; 262: 145-156.Coronary artery disease and type 2 diabetes are chronic diseases of substantial and growing prevalence. Their coincidence is common, markedly enhancing mortality and morbidity. The risk for cardiovascular disease increases along a spectrum of blood glucose concentrations already apparent at levels regarded as normal. Accordingly, strategies for the early detection of glucometabolic disturbances are needed to find ways to prevent the occurrence of cardiovascular complications or to treat them already at an early stage. More specifically, abnormal glucose tolerance is almost twice as common amongst patients with a myocardial infarction as in population-based controls and a normal glucose regulation is indeed less common than abnormal glucose metabolism also amongst patients with stable coronary artery disease. Already an abnormal glucose tolerance is a strong risk factor for future cardiovascular events after an acute myocardial infarction. An oral glucose tolerance test should, therefore, be a part of the evaluation of total risk in all patients with coronary artery disease. As glucose disturbances are common and easy to detect, they may be suitable targets for novel secondary preventive efforts.